/l was 10 and to a platelet count Ͼ20 ؋ 10 9 /l was 14. Neutropenic fevers developed in 16 patients. There were no hemorrhagic episodes. A total of 69 cycles of doxorubicin and taxol were delivered (87% of planned). The median time from PBSC infusion to the first cycle was 38 days. The median time to the second cycle was 27 days and to the last cycle was 24 days. One patient developed congestive heart failure. Two episodes of neutropenic fevers were observed. No toxicity-related deaths were observed. Grafts are stable at 6 months post transplantation. This multistep regimen is feasible with acceptable toxicity. Keywords: metastatic breast cancer; high-dose chemotherapy; post-transplant doxorubicin, taxol Metastatic breast carcinoma (MBC) remains an incurable disease. Although high-dose chemotherapy (HDC) and stem cell transplantation is well tolerated in patients with advanced breast carcinoma, this modality has not been effective in preventing disease progression in the majority of this patient population. High-dose chemotherapy pro- grams have consisted mainly of standard-dose induction therapy followed by one or occasionally two doses of HDC for patients who first achieve an objective response with an induction treatment. With this strategy 10-20% of patients are disease free at 4-5 years.
grams have consisted mainly of standard-dose induction therapy followed by one or occasionally two doses of HDC for patients who first achieve an objective response with an induction treatment. With this strategy 10-20% of patients are disease free at 4-5 years. 1 However, it can be argued that by using an induction phase this may allow expansion of populations that are only partially sensitive to HDC, compromising the ability of the patients to be cured. If this is correct HDC should be used as initial therapy and not after induction treatment. At least 87 patients with metastatic breast cancer have received high-dose chemotherapy as initial therapy. Response rates of 55% were obtained with 33% of patients remaining in complete continuous remission from 11 to 120 months. 1, 2 The main cause of treatment failure following HDC is relapse. We have been interested in determining whether consolidation therapy can be administered shortly after HDC and if this approach translates in an increased response rate and also overall survival and disease-free survival. We have shown in a previous trial that three cycles of standard-dose doxorubicin can safely be administered post transplant. 3 The favorable outcome with respect to toxicity of such an approach has enabled us to design a new trial in which doxorubicin and taxol are used in combination as consolidation therapy following HDC and autologous stem cell transplantation.
Patients and methods
The protocol was approved by the Institutional Review Board for Biomedical Research at the University of Pittsburgh. Informed written consent was obtained from all the patients prior to entry into the study.
Patient eligibility
Eligibility criteria included: histologically proven metastatic breast carcinoma; age less than 65 years old; Eastern Cooperative Oncology Group performance status of 0 or 1; no brain metastases; less than 250 mg/m 2 of cumulative doxorubicin; cardiac ejection fraction greater than 50%; adequate pulmonary function including carbon monoxide diffusion capacity of more than 60%; serum creatinine of less than 1.5 mg/dl; no prior chemotherapy for metastatic disease; failure of one or more hormonal manipulations in patients with ER-positive receptors with bone and/or soft tissue disease alone.
Treatment plan
The study design is depicted in Table 1 . The study consisted of three steps. In step I, the patients were admitted to the hospital and a double lumen leukapheresis vascular catheter was inserted into the subclavian vein. Patients were hydrated and treated with cyclophosphamide at 5000 mg/m 2 given as a continuous intravenous infusion over 24 h and etoposide at 1000 mg/m 2 over 8 h. All patients were given 2-mercaptoethane sulfonate (MESNA) as uroprotection. Immediately upon completion of chemotherapy G-CSF (Neupogen, Amgen, Thousand Oaks, CA, USA) was administered daily at 5 g/kg by subcutaneous injection. When the leukocyte count recovered to 1 ϫ 10 9 /l, leukapheresis to harvest PBSCs was initiated (Cobe Spectra; Cobe BCT, Lakewood, CO, USA) until 10 ϫ 10 6 CD34-positive cells /kg were obtained. The PBSC product was cryopreserved in the usual manner. Patients were then readmitted to the hospital for step II of the study. Highdose chemotherapy (CTCb) was then administered. Patients received cyclophosphamide (1500 mg/m 2 daily) on days Ϫ6, Ϫ5, Ϫ4 and Ϫ3, thiotepa (125 mg/m 2 daily) on days Ϫ6, Ϫ5, Ϫ4 and Ϫ3, and carboplatin 200 mg/m 2 on days Ϫ6, Ϫ5, Ϫ4 and Ϫ3. These drugs were delivered intravenously via continuous infusion. MESNA uroprotection at 1500 mg/m 2 was administered daily from day Ϫ6 to day Ϫ2. PBSCs were infused on day 0 and daily G-CSF was reinstated at 5 g/kg/day on day +1 and continued until the patient achieved a sustained neutrophil count of greater than 1 ϫ 10 9 /l for 3 days.
Step III was initiated after patients recovered from any GI toxicity (grade I or better) and after patients achieved an absolute neutrophil count (ANC) of equal to or more than 1.5 ϫ 10 9 /l and a platelet count of more than 100 ϫ 10 9 /l. It consisted of three cycles of doxorubicin at 50 mg/m 2 delivered intravenously and taxol 150 mg/m 2 delivered intravenously over 3 h every 3 weeks. Patients receive G-CSF at 5 g/kg by subcutaneous injection from day 3 to day 12 of each cycle.
Supportive care
During the second phase of the study, all patients were cared for in private rooms with positive pressure, high efficiency particle filtration (HEPA) air system. Antimicrobial prophylaxis with ciprofloxacin and fluconazole was Table 1 Study design
Step /l.
Hematopoietic progenitor cells
The total number of CD34 + and lineage negative (CD34 + lin Ϫ ) cells was determined in daily peripheral blood stem cell products by flow cytometry by staining cells with two anti-CD34, fluorescein isothiocyanate-conjugated monoclonal antibodies, 8G12 (Becton Dickson, San Jose, CA, USA) and Qbend-10 (Gen Track, Plymouth, PA, USA) and four lineage-specific phycoerythrin-conjugated monoclonal antibodies with specificities for CD3, CD11B, CD14 and CD19 (Becton Dickson, San Jose, CA, USA).
Response criteria, toxicity and statistical analysis
All patients were considered evaluable for toxicity. Toxicity was graded according to the National Cancer Institute common criteria. Complete response (CR) was defined as the complete disappearance of all evidence of tumor, including normalization of laboratory parameters. Partial response (PR) was defined as 50% or greater reduction in the sum of the perpendicular diameters of measurable lesions without evidence of progression. The persistence of uptake on bone scan despite sclerosis of previous lytic lesions was defined as PR. Stable disease (SD) was tumor regression not fulfilling the requirements of partial remission or progression. Progressive disease (PD) was defined as the appearance of new lesions or a greater than 25% increase in measurable lesions. Progression-free and overall survival rates were estimated from the start of high-dose cyclophosphamide, using the Kaplan-Meier 4 approach.
Results

Patients
Twenty-four patients were enrolled in the study between March 1992 and December 1995. Patient characteristics are listed in Tables 2 and 3 . The median age of the patients in this study was 47 (range 32-65). Dominant sites of metastasis included visceral (46%), soft tissue (25%) and bone (29%). Fifty-five percent of the patients with dominant soft tissue or bone disease were ER negative. Thirteen patients had one site of disease involvement at the time of enrolment while five patients had two sites of involvement and six patients had three or more sites. Fifteen patients received adjuvant chemotherapy. In 13 of these patients adjuvant chemotherapy was delivered 2 years or more prior to enrolment. The first presentation of five patients was metastatic disease and they were chemotherapy naïve. Peripheral blood stem cell collection Leukapheresis was performed in 23 patients following mobilization chemotherapy with high-dose cyclophosphamide and etoposide and G-CSF and was devoid of significant morbidity. A median of 23 ϫ 10 6 /kg CD34-positive cells (range 7.3-64.1) were collected. One patient developed septic thrombophlebitis with positive blood cultures for methicillin-resistant Staphylococcus aureus treated with 6 weeks of antibiotics. This patient was subsequently mobilized with G-CSF 10 g/kg subcutaneously. The median number of leukapheresis procedures was 2 (range 1-10).
Toxicity
Mobilization chemotherapy: All 24 patients completed the initial mobilization chemotherapy consisting of high dose cyclophosphamide and etoposide. Grade II-III gastrointestinal toxicity was observed in six of the 24 patients. Ten patients (42%) developed neutropenic fevers and were treated with broad-spectrum antibiotics. There was only one episode of documented bacteremia. In addition, one patient developed septic thrombophlebitis with methicillin-resistant Staphylococcus aureus requiring 6 weeks of intravenous antibiotics. The median time to initiation of leukapheresis was 13 days (range 10-18).
High-dose chemotherapy:
Twenty-three patients received high-dose chemotherapy with CTCb. One patient developed catheter-associated thrombosis after leukapheresis and refused to proceed with the study. Grade II-III GI toxicity was observed in seven of 23 patients. Neutropenic fevers developed in 16 patients. There were four episodes of documented bacteremia. Three of those episodes were due to gram positive cocci. However, one episode was due to Pseudomonas aeruginosa. The median number of days to recover a neutrophil count greater than 0.5 ϫ 10 9 /l was 10 (range 7-23). The median number of days to a platelet count greater than 20 ϫ 10 9 /l was 14 (range 9-29). The median number of RBC transfusions was four (range 0-14) and the number of platelet transfusions was 12 (range 0-42). No hemorrhagic complication or veno-occlusive disease was observed. No deaths related to the administration of CTCb were observed.
Post-transplant doxorubicin and taxol:
Of the 23 patients who completed CTCb two did not receive post-transplant therapy. One patient had developed Pseudomonas aeruginosa bacteremia requiring a long course of intravenous antibiotics and decided not to proceed with this step of the study. Another patient developed a drop in the left ventricular ejection fraction post CTCb and for that reason initiation of doxorubicin and taxol was postponed. However, prior to initiation of this post-transplant therapy, the patient developed idiopathic interstitial pneumonitis from which she eventually recovered, yet she elected not to complete the three cycles of post-transplant therapy. One patient developed an anaphylactic reaction with the first cycle of taxol and for that reason the two subsequent cycles were delivered with doxorubicin alone. One patient received two cycles of planned doxorubicin/taxol therapy post transplant but developed a viral pneumonia and elected not to receive the third cycle. A total of 69 cycles of doxorubicin and taxol were delivered (87% of planned).
Two episodes of culture negative neutropenic fevers were observed. One patient developed congestive heart failure 4 months after completing her last cycle of doxorubicin/taxol. The left ventricular ejection fraction dropped from 60% prior to initiation of the study to 25% at the time symptoms developed. The left ventricular ejection fraction was normal prior to starting post-transplant chemotherapy. At 11 months post-transplant and 7 months after completing the last course of doxorubicin/taxol symptoms were controlled with medication. The median time from the day of PBS infusion in the first cycle of post-transplant therapy was 38 days (range 22-90). Median time from the first post-transplant dose to the second was 21 days (range 21-23). Median time from the second cycle to the third was 24 days (range 21-28). Grafts are stable at 6 months post-transplantation with patients having normal platelet count as well as normal leukocyte count.
Response
Restaging was performed after completion of all three steps of the study. Of the 23 patients who completed CTCb, 21 proceeded with post-transplant doxorubicin and taxol. Of these 21 patients, 18 received all three planned cycles of post-transplant therapy. Twenty-one patients had adequate follow-up. For these 21 patients the overall response rate was 66% with 33% CRs and 33% PRs. Five of the six patients in CR after completion of therapy remain free of disease at 5, 7, 9, 10 and 18 months, respectively, post therapy. One patient progressed at 9 months. Of the patients who achieved a PR, two have progressed at 13 and 8 months post transplant. One of these patients had mainly bone disease and the other had visceral disease with liver involvement. Survival and disease-free survival curves are shown in Figures 1 and 2 .
Discussion
The timing of high-dose chemotherapy and stem cell transplant for breast carcinoma is controversial. It is unclear how much chemotherapy, if any, should be administered prior to HDC. In the majority of published studies standard-dose chemotherapy is used as induction therapy to decrease tumor bulk and to allow for the selection of patients with chemosensitive disease. With such strategy 10-20% of patients with sensitive disease are disease free at 4-5 years after HDC. [5] [6] [7] [8] However, it can be argued that using an induction phase allows the expansion of resistant clones that are only partially sensitive to HDC, thus compromising the ability of patients to be cured. 9, 10 The use of upfront HDC for patients with metastatic disease produces response rates of 55% with 33% of the patients remaining in complete continuous remissions from 11 to 120 months. 11 In this trial we were interested in determining whether consolidation therapy could be administered shortly after upfront HDC. The combination of high-dose cyclophosphamide and etoposide followed by G-CSF was used as mobilization regimen. Its administration was free of significant morbidity and allowed the collection of PBSCs at the beginning of hematologic recovery, in accordance with the results previously reported by several investigators. 12, 13 Neutropenic fevers were a common complication of this mobilization regimen. Forty-two percent of the patients experienced neutropenic fevers, however, only one patient demonstrated positive blood cultures. The second step of our study included the use of high-dose chemotherapy with peripheral stem cell transplant rescue. As a conditioning regimen we used CTCb, a regimen previously described by Antman. 1 The number of days to recover a neutrophil count of Ͼ0.5 × 10 9 /l was 10 and a platelet count Ͼ20 × 10 9 /l was 14. This relatively short time to neutrophil and platelet recovery reflects the use of PBSC instead of bone marrow as hematopoietic rescue and is similar to results previously reported using the same preparative regimen. 14 Of the 23 patients who completed CTCb two did not receive post-transplant doxorubin and taxol. The first course of doxorubicin and taxol could be delivered on average by 38 days post-transplant. Chemotherapy soon after transplantation has rarely been considered due to concerns of toxicity to the marrow progenitors. 3, 15 The human multidrug resistance gene has been transduced into human marrow progenitors and the transduced cells exhibit preferential resistance to taxol. In the context of a genetic chemoprotection trial, Rahman et al have administered escalating doses of taxol post-transplant with the goal of eradicating minimal residual disease. They showed that they could deliver the first cycle within a median of 30 days post stem cell reinfusion. In our current trial 87% of the planned cycles of doxorubicin and taxol were administered and all grafts are stable at 6 months post-transplant. A total of 83 cycles of escalating doses of taxol were administered to 10 patients.
Our trial differs from the majority of previously reported trials, as no induction standard-dose of chemotherapy was administered upfront in an attempt to select patients to proceed with HDC. Our study population consisted of chemotherapy-naive patients with metastatic disease. Response rates obtained with this approach are similar to published responses for HDC in patients who have sensitive disease after induction chemotherapy. The relative contribution to response of each of the steps of this trial is unknown since all the patients were restaged only after completion of all three steps. In an attempt to elucidate better the contribution to disease response of each therapeutic component of this trial a phase II study is currently ongoing. Patients will be restaged after each step of the study with radiologic studies and in patients with bone marrow involvement with repeated biopsies. Our study raises some interesting issues related to timing of the administration of HDC, namely whether upfront HDC is better than induction therapy followed by HDC and whether post-transplant chemotherapy is of value. These questions will only be fully answered by randomized controlled trials.
In conclusion post-transplant doxorubicin and taxol can be safely administered shortly post-transplantation without further stem cell support.
